Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 8/20 | 0.39 |
| ▸ | NPC1 | O15118 | 6/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19067622 | 0.84 | ALDH1A1 (0.40) | SMN1; SMN2HPGDHSD17B10RAB9ANPC1 | |
| SCHEMBL17232511 | 0.83 | NOTUM (0.38) | SMN1; SMN2HPGDF10RAB9ANPC1 | |
| SCHEMBL14397997 | 0.82 | RAB9A (0.37) | SMN1; SMN2HPGDHSD17B10RAB9ANPC1 | |
| SCHEMBL10130863 | 0.82 | RAB9A (0.42) | SMN1; SMN2HPGDHSD17B10RAB9ANPC1 | |
| SCHEMBL3369897 | 0.80 | NOTUM (0.38) | SMN1; SMN2F10RAB9ANPC1ALDH1A1 | |
| SCHEMBL4068333 | 0.80 | NOTUM (0.57) | SMN1; SMN2HPGDHSD17B10F10RAB9A | |
| SCHEMBL10130868 | 0.78 | ALDH1A1 (0.40) | SMN1; SMN2HPGDHSD17B10RAB9ANPC1 | |
| SCHEMBL27572915 | 0.77 | F10 (0.37) | SMN1; SMN2HSD17B10F10RAB9ANPC1 | |
| SCHEMBL17229343 | 0.76 | F10 (0.51) | F10MAPK1 | |
| SCHEMBL8270603 | 0.74 | HSD17B10 (0.43) | SMN1; SMN2HPGDHSD17B10F10RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9695166-B2 | Pyrazolopyridine pyrazolopyrimidine and related compounds | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20150315198-A1 | PYRAZOLOPYRIDINE PYRAZOLOPYRIMIDINE AND RELATED COMPOUNDS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2015-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315198-A1 | PYRAZOLOPYRIDINE PYRAZOLOPYRIMIDINE AND RELATED COMPOUNDS | TPMT, DPYD, XDH | SMN1; SMN2 1408/4885HPGD 1636/4885HSD17B10 3671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.